← All trials
NCT04324372
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2019
- Primary completion
- Feb 27, 2021
- Completion date
- Oct 17, 2021
- First posted
- Mar 27, 2020
- Last posted
- Mar 27, 2020
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.